readthroughSign in
CompanyIBRXNasdaqSan Diego, CA

ImmunityBio, Inc.

ImmunityBio develops immunotherapies including an IL-15 superagonist, adenovirus-vectored vaccines, and allogeneic and autologous NK-cell therapies for cancer and infectious diseases.

10-QNov 16Latest SEC filing
Nov 10Latest story